Evidence map›Paper›PMID 40832334›Full record

ArticlebioRxiv : the preprint server for biology2025

Paired plus-minus sequencing is an ultra-high throughput and accurate method for dual strand sequencing of DNA molecules.

Alexandre Pellan Cheng, Itai Rusinek, Aaron Sossin, Adam J Widman, Eti Meiri, Gat Krieger, Ori Hirschberg, Doron Shem Tov, Shlomit Gilad, Ariel Jaimovich and 27 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Alexandre Pellan ChengÉcole de Technologie Supérieure, Montréal, Québec, Canada.ORCID 0000-0002-3667-0992
Itai RusinekUltima Genomics, Fremont, California, United States.ORCID 0000-0001-5027-5764
Aaron SossinNew York Genome Center, New York, NY, United States.ORCID 0000-0003-2546-3389
Adam J WidmanNew York Genome Center, New York, NY, United States.ORCID 0000-0001-7953-0677
Eti MeiriUltima Genomics, Fremont, California, United States.
Gat KriegerUltima Genomics, Fremont, California, United States.
Ori HirschbergUltima Genomics, Fremont, California, United States.
Doron Shem TovUltima Genomics, Fremont, California, United States.
Shlomit GiladUltima Genomics, Fremont, California, United States.ORCID 0000-0001-5103-1649
Ariel JaimovichUltima Genomics, Fremont, California, United States.
Omer BaradUltima Genomics, Fremont, California, United States.
Sammantha AvaylonNew York Genome Center, New York, NY, United States.ORCID 0000-0001-9921-0347
Srinivas RajagopalanNew York Genome Center, New York, NY, United States.ORCID 0000-0003-3599-0414
Catherine PotenskiNew York Genome Center, New York, NY, United States.ORCID 0000-0002-4843-7071
Tamara PrietoNew York Genome Center, New York, NY, United States.ORCID 0000-0002-1181-9156
Dennis J YuanNew York Genome Center, New York, NY, United States.ORCID 0000-0002-6979-6700
Rob FurateroNew York Genome Center, New York, NY, United States.
Alexi RunnelsNew York Genome Center, New York, NY, United States.ORCID 0000-0002-8592-1444
Benjamin M CostaCenter for Human Genetics and Genomics, New York University Grossman School of Medicine, New York, NY, USA.
Jonathan E ShoagDepartment of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.ORCID 0000-0002-3119-9986
Majd Al AssaadEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-9512-0253
Michael SigourosEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-0328-8359
Jyothi ManoharEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0001-6357-910X
Abigail KingEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
David WilkesEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
John OtilanoEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Murtaza S MalbariSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, United States.
Olivier ElementoEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-8061-9617
Juan Miguel MosqueraEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-4666-6476
Nasser K AltorkiSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, United States.ORCID 0000-0001-9754-9945
Ashish SaxenaSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, United States.
Margaret K CallahanMemorial Sloan Kettering Cancer Center, New York, NY, United States.
Nicolas RobineNew York Genome Center, New York, NY, United States.ORCID 0000-0001-5698-8183
Soren GermerNew York Genome Center, New York, NY, United States.ORCID 0000-0002-6038-8508
Gilad D EvronyCenter for Human Genetics and Genomics, New York University Grossman School of Medicine, New York, NY, USA.ORCID 0000-0001-7621-2630
Bishoy M FaltasSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, United States.ORCID 0000-0002-6432-1693
Dan-Avi LandauNew York Genome Center, New York, NY, United States.ORCID 0000-0003-2346-9541

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
New York Genome Characterization Center: Somatic Mosaicism across Human TissuesUM1DA058236 · NIDA · NEW YORK GENOME CENTER · PI Samuel Aparicio, Nicolas Robine · 2023 to 2026
$11.8M
Genome-wide mutational integration for ultra-sensitive plasma tumor burden monitoring in immunotherapyR01CA266619 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Dan Landau, Nicolas Robine · 2022 to 2026
$3.2M
Ultra-High Fidelity Single-Molecule Profiling of Mosaic Double- and Single-Strand DNA Mutations and DamageUH3NS132024 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Gilad David Evrony · 2025 to 2026
$1.3M
Ultra-High Fidelity Single-Molecule Profiling of Mosaic Double- and Single-Strand DNA Mutations and DamageUG3NS132024 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI EVRONY, GILAD DAVID · 2023 to 2024
$859k
Single-Cell Multi-omics to Link Clonal Mosaicism (CM) Genotypes with Chromatin, Epigenomic, Transcriptomic and Protein PhenotypesUG3NS132139 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI LANDAU, DAN, SATIJA, RAHUL · 2023 to 2024
$834k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA266619NIDA NIH HHS UM1 DA058236NINDS NIH HHS UG3 NS132024NINDS NIH HHS UG3 NS132139NINDS NIH HHS UH3 NS132024
6 · The paper itself

Abstract

Distinguishing real biological variation in the form of single-nucleotide variants (SNVs) from errors is a major challenge for genome sequencing technologies. This is particularly true in settings where SNVs are at low frequency such as cancer detection through liquid biopsy, or human somatic mosaicism. State-of-the-art molecular denoising approaches for DNA sequencing rely on duplex sequencing, where both strands of a single DNA molecule are sequenced to discern true variants from errors arising from single stranded DNA damage. However, such duplex approaches typically require massive over-sequencing to overcome low capture rates of duplex molecules. To address these challenges, we introduce paired plus-minus sequencing (ppmSeq) technology, in which both DNA strands are partitioned and clonally amplified on sequencing beads through emulsion PCR. In this reaction, both strands of a double-stranded DNA molecule contribute to a single sequencing read, allowing for a duplex yield that scales linearly with sequencing coverage across a wide range of inputs (1.8-98 ng). We benchmarked ppmSeq against current duplex sequencing technologies, demonstrating superior duplex recovery with ppmSeq, with a rate of 44%±5.5% (compared to ~5-11% for leading duplex technologies). Using both genomic as well as cell-free DNA, we established error rates for ppmSeq, which had residual SNV detection error rates as low as 7.98x10

Identifiers

PMID40832334
PMCPMC12363824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.